Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D81WBS
|
|||
| Drug Name |
PF-07038124
|
|||
| Synonyms |
PF-07038124; M6ZU548FWD; PF07038124; UNII-M6ZU548FWD; 2415085-44-6; Pyridine, 3-((4R)-2-hydroxy-1,2-oxaborolan-4-yl)-5-(4-methoxy-3-propoxyphenyl)-; GTPL11950; US11559538, Example 4; BDBM589740; GLXC-25702; Example 4 [US2020108083A1]; PF 07038124 [WHO-DD]; HY-144683; CS-0433935; (R)-4-(5-(4-Methoxy-3-propoxyphenyl)pyridin-3-yl)-1,2-oxaborolan-2-ol; 3-[(4R)-2-hydroxyoxaborolan-4-yl]-5-(4-methoxy-3-propoxyphenyl)pyridine
Click to Show/Hide
|
|||
| Drug Type |
Small molecule
|
|||
| Indication | Atopic dermatitis [ICD-11: EA80; ICD-10: L20] | Phase 2 | [1] | |
| Psoriasis [ICD-11: EA90] | Phase 2 | [1] | ||
| Company |
Pfzer
|
|||
| Structure |
 |
Download2D MOL
|
||
| Formula |
C18H22BNO4
|
|||
| Canonical SMILES |
B1(CC(CO1)C2=CN=CC(=C2)C3=CC(=C(C=C3)OC)OCCC)O
|
|||
| InChI |
InChI=1S/C18H22BNO4/c1-3-6-23-18-8-13(4-5-17(18)22-2)14-7-15(11-20-10-14)16-9-19(21)24-12-16/h4-5,7-8,10-11,16,21H,3,6,9,12H2,1-2H3/t16-/m0/s1
|
|||
| InChIKey |
KXVKOYCGACSUPP-INIZCTEOSA-N
|
|||
| PubChem Compound ID | ||||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Phosphodiesterase 4 (PDE4) | Target Info | Inhibitor | [2] |
| References | Top | |||
|---|---|---|---|---|
| REF 1 | ClinicalTrials.gov (NCT05375955) A PHASE 2B, RANDOMIZED, DOUBLE BLIND, VEHICLE CONTROLLED, PARALLEL GROUP STUDY TO ASSESS THE EFFICACY, SAFETY, TOLERABILITY AND PHARMACOKINETICS OF MULTIPLE DOSE LEVELS OF PF-07038124 OINTMENT FOR 12 WEEKS IN PARTICIPANTS 12 YEARS AND OLDER AND WITH MILD-TO-MODERATE ATOPIC DERMATITIS OR MILD-TO-SEVERE PLAQUE PSORIASIS. U.S.National Institutes of Health. | |||
| REF 2 | Clinical pipeline report, company report or official report of Pfzer | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.